Anavex Life Sciences Corp buy melinda
Start price
21.10.20
/
50%
€4.28
Target price
04.11.21
€6.00
Performance (%)
348.60%
End price
05.11.21
€19.20
Summary
This prediction ended on 05.11.21 with a price of €19.20. The BUY prediction by melinda for Anavex Life Sciences Corp saw massive gains of 348.60%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Anavex Life Sciences Corp | 2.210% | 2.210% | -23.092% | -65.173% |
iShares Core DAX® | 1.665% | 1.692% | 18.093% | 15.353% |
iShares Nasdaq 100 | -0.475% | 1.483% | 27.860% | 36.314% |
iShares Nikkei 225® | 2.620% | 4.475% | 17.651% | 10.750% |
iShares S&P 500 | -0.091% | 1.099% | 24.873% | 36.740% |
According to melinda what are the pros and cons of Anavex Life Sciences Corp for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Anavex Life Sciences Corp diskutieren
Buy mit Kursziel 6,0
In the thread Trading Anavex Life Sciences Corp
Die von melinda gewählte maximale Laufzeit wurde überschritten
Stopped prediction by melinda for Anavex Life Sciences Corp
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€3.46
29.08.20
29.08.20
€4.50
21.10.20
21.10.20
23.70%
21.10.20
21.10.20
Could be worthwhile Investment >10% per year
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€4.00
05.11.17
05.11.17
€4.51
15.02.18
15.02.18
-41.44%
15.02.18
15.02.18
Could be worthwhile Investment >10% per year
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€4.44
05.11.17
05.11.17
€5.00
15.02.18
15.02.18
-41.44%
15.02.18
15.02.18
Could be worthwhile Investment >10% per year
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€5.23
27.02.17
27.02.17
€9.02
23.03.17
23.03.17
1.74%
23.03.17
23.03.17
Could be worthwhile Investment >10% per year
Anavex Life Sciences Corp
Start price
Target price
Perf. (%)
€4.05
10.05.16
10.05.16
€4.96
30.06.16
30.06.16
22.85%
30.06.16
30.06.16
Could be worthwhile Investment >10% per year